



May 9, 2023

Press Release

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth Market)

TMS Co., Ltd. signed Option Agreement with Hokkaido University

TMS Co., Ltd. (the “Company”) announces that the Company has signed an Option Agreement with Hokkaido University on May 8, 2023 for the evaluation and licensing of drug candidate compounds.

Under the terms of this agreement, the Company obtains an exclusive right to evaluate the compounds being developed by Hokkaido University for an agreed period of time, as well as an exclusive right to negotiate licensing. The Company pays an upfront payment to Hokkaido University.

The Company has been conducting extensive search for early-stage drug candidates mainly from academia, as a part of pipeline expansion activities. The identified compounds have demonstrated efficacy in animal models of target indications. In addition, the Company expects that the compounds have potential to be applied to a wide range of diseases based on the pharmacological actions.

This is the second option deal between the Company and the Hokkaido University. The deal was assisted by Gemseki, Inc. (<https://www.gemseki.com/en/>), a subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), a listed nonclinical contract research organization in Japan.

The impact of this matter on the company's business performance for the current fiscal year is expected to be minimal.

About TMS Co., Ltd.

TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address medical unmet needs. The Company’s pipeline consists of a family of small compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived from a fungus. The lead pipeline, TMS-007, is indicated for the treatment of acute ischemic stroke. It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipelines by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit www.tms-japan.co.jp/en.

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Investor and Media Contact:
ir@tms-japan.co.jp

End